CJC/IPA Blend 10mg

CJC/IPA Blend — GHRH + Secretagogue Dual Stack

The CJC-1295 and Ipamorelin blend combines two complementary growth hormone-stimulating peptides into a single research formulation. By pairing a GHRH analog (CJC-1295) with a selective GH secretagogue (Ipamorelin), this blend targets both the stimulatory and amplification pathways of pituitary GH release — producing a synergistic effect that exceeds either compound used alone.

Dual Mechanism of Action

CJC-1295 binds to GHRH receptors on pituitary somatotrophs, activating cAMP-dependent transcription of the GH gene and priming the cell for hormone release. Ipamorelin engages the ghrelin/GHS receptor (GHSR), triggering an independent calcium-dependent release mechanism. When both pathways are activated simultaneously, the result is amplified GH secretion with preserved pulsatility — the natural pattern of GH release that is critical for physiological signaling.

Synergy Profile

The CJC/IPA combination is studied for producing greater GH output than additive doses of either peptide alone. Ipamorelin’s selectivity (no cortisol, prolactin, or appetite stimulation) makes it an ideal pairing partner, as it amplifies CJC-1295’s signal without introducing confounding hormonal variables.

Research Applications

• Synergistic GH release and pulsatility studies
• GHRH + GHSR co-activation mechanisms
• IGF-1 axis amplification research
• Body composition and lean mass investigations
• Sleep architecture and nocturnal GH secretion studies

Product Specifications

• Quantity: 10mg total (CJC-1295 + Ipamorelin blend)
• Purity: ≥99% (HPLC verified)
• Form: Lyophilized powder
• Storage: Refrigerate after reconstitution